Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia - 2ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- 3Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
- 4French high-speed train slams into truck, killing TGV driver
- 5Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- Understanding Preschool Projects: An Extensive Aide
- Seven deaths possibly linked to malfunctioning glucose monitors
- Polls open in tense Uganda election amid widespread delays
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- The Extraordinary Excursion of Dental Embed Innovation
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Seoul says sorry after unapproved drone flights into North Korea
